Monday, 31 August 2026European Markets

MOREFIELD GROUP Stock Impressive Rise On Tuesday, Outperforms Market

Loading stream...

(VIANEWS) - The Market ended the session with MOREFIELD GROUP (MORE.AS) rising 11.7% to €0.53 on Tuesday while AEX-Index rose 0.14% to €878.40.

MOREFIELD GROUP's last close was €0.47, 2.17% higher than its 52-week high of €0.46.

About MOREFIELD GROUP

Morefield Group N.V. through its subsidiary Kersten Groep BV, engages in the selecting, advising, supplying, and maintaining medical aids for physical disability peoples. The company manufactures orthoses, such as braces and splints. It serves to municipalities, care administration offices, health insurers, and care institutions/care organizations. The company was formerly known as HeadFirst Source Group N.V. and changed its name to Morefield Group N.V. in January 2019. Morefield Group N.V. was incorporated in 1983 and is headquartered in Willemstad, Curaçao.

Earnings Per Share

As for profitability, MOREFIELD GROUP has a trailing twelve months EPS of €0.1.

PE Ratio

MOREFIELD GROUP has a trailing twelve months price to earnings ratio of 5.25. Meaning, the purchaser of the share is investing €5.25 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 43.55%.

More news about MOREFIELD GROUP (MORE.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com